Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$6.78B+103.91%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bernhard Montag
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 74,600
- Beta
- 0.83
- Country
- DE
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.01
Financials
Revenue
$6.78B+103.9%Net Income
$589.00M+64.1%EBITDA
$1.20B+64.9%Free Cash Flow
$703.00M+294.9%EPS (diluted)
$0.53+47.2%Shares Outstanding (diluted)
1.11B+11.1%Operating Expenses
$1.59BCash & Debt
$2.96BReturn of Capital
$54.00MDividend per Share
$1.19Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $23.63B | $2.21B | $1.98 |
| 2025 | $23.42B | $2.15B | $1.92 |
| 2024 | $22.36B | $1.94B | $1.74 |
| 2023 | $21.68B | $1.51B | $1.35 |
| 2022 | $21.71B | $2.04B | $1.82 |
| 2021 | $18.00B | $1.73B | $1.57 |
| 2020 | $14.46B | $1.41B | $1.41 |
| 2019 | $14.52B | $1.57B | $1.57 |
| 2018 | $13.43B | $1.26B | $1.27 |
| 2017 | $13.68B | $1.38B | $1.38 |
| 2016 | $13.55B | $1.31B | $1.31 |
| 2015 | $12.94B | $1.28B | $1.28 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SEMHF's reported EPS growth of 4.0% a year over 11 years.
- EPS in 5 years
- $2.41
- Implied price
- $48.18
- Return from $46.87
- 0.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $23.95 — -48.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -6.0% | -15.4% | -12.0% | -9.1% | -6.5% | -4.2% |
| -1.0% | -10.9% | -7.3% | -4.3% | -1.6% | 0.9% |
| 4.0% | -6.4% | -2.7% | 0.6% | 3.4% | 6.0% |
| 9.0% | -1.9% | 2.0% | 5.4% | 8.4% | 11.1% |
| 14.0% | 2.6% | 6.7% | 10.2% | 13.3% | 16.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
150+400.00%Social Signal Score
Mentions (5)
- Newswsj.com·17d ago·Neutral
Siemens Healthineers to Rebrand as Healthineers as Diagnostics Carve-Out Begins The medical-technology company will drop Siemens from its name as it advances toward a spinoff from its parent group.
View source ↗ - Newsreuters.com·17d ago·Neutral
Siemens Healthineers starts carve-out of diagnostics business Siemens Healthineers starts carve-out of diagnostics business
View source ↗ - Newsreuters.com·17d ago·Neutral
Siemens Healthineers expects FY2027 revenue growth of 4%-5% Siemens Healthineers expects FY2027 revenue growth of 4%-5%
View source ↗ - Newsbusinesswire.com·56d ago·Negative
Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens Healthineers MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts and clinical partners for interoperability with the company's new radiotherapy system, Accela. Unveiled at the annual ASTRO conference, Accela is the first software-driven deliv
View source ↗ - Newsseekingalpha.com·91d ago·Positive
Siemens Healthineers: Successful Investment, Updating For H2 2026 Siemens Healthineers remains a high-conviction BUY with a reiterated €48/share price target, reflecting strong Imaging and Precision Therapy segments. I exclude Chinese recovery from my base case; growth is now driven by ex-China Imaging and Varian, with diagnostics seen as structurally impaired. 3Q26 results confirmed robust order momentum (1.3x book-to-bill), and margin strength (19.1%), and EPS guidance raised to €2.45, though
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $0.55 per share
Typical surprise +2.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.78 vs $0.76beat
- Fri, Jul 31$0.80 vs $0.60beat
- Thu, May 7$0.61 vs $0.58beat
- Thu, Feb 5$0.58 vs $0.52beat
- Wed, Nov 5$0.62 vs $0.81miss
- Wed, Jul 30$0.58 vs $0.63miss
Estimates and results for SEMHF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in SEMHF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
